Rosemarie A Martin1, Damaris J Rohsenow2, Jennifer W Tidey1. 1. Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, RI 02912, USA. 2. Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, RI 02912, USA. Electronic address: Damaris_Rohsenow@Brown.edu.
Abstract
INTRODUCTION:Smokers with opioid use disorder (OUD) have little success with smoking cessation, possibly due to interactions between nicotine and opioid receptor systems. Smokers with OUD versus non-opioid substance use disorders (NOUD) have not been compared for response to smoking treatment. Data to make this comparison came from our previous study of 12 weeks (plus dose run-up) of varenicline (VAR) versus 12 weeks of nicotine patch (NRT), in a double-placebo design. METHODS: The current study reports secondary analyses comparing smokers with OUD (n = 47) and NOUD (n = 90) on pretreatment smoking, alcohol and drug use, intolerance of physical discomfort, smoking medication adherence, and 3- and 6-month smoking and substance use outcomes (by VAR versus NRT). RESULTS:Smokers with OUD did not differ on pretreatment alcohol or smoking measures while reporting significantly more drug use days. Smokers with OUD versus NOUD had significantly fewer days adherent to VAR or placebo capsules but not to patches, and were more tolerant of physical discomfort. While smoking and heavy drinking days at follow-ups did not differ by diagnosis, smokers with OUD had significantly more drug use days in months 4-6 when assigned to VAR (16.4 days) than to NRT (8.1 days). CONCLUSIONS: NRT might be a better choice than VAR for smokers with OUD due to lower adherence and more drug use days with VAR. However, this novel comparison of smoking pharmacotherapy response in smokers with OUD versus NOUD needs to be confirmed with larger numbers of participants. Published by Elsevier Inc.
RCT Entities:
INTRODUCTION: Smokers with opioid use disorder (OUD) have little success with smoking cessation, possibly due to interactions between nicotine and opioid receptor systems. Smokers with OUD versus non-opioid substance use disorders (NOUD) have not been compared for response to smoking treatment. Data to make this comparison came from our previous study of 12 weeks (plus dose run-up) of varenicline (VAR) versus 12 weeks of nicotine patch (NRT), in a double-placebo design. METHODS: The current study reports secondary analyses comparing smokers with OUD (n = 47) and NOUD (n = 90) on pretreatment smoking, alcohol and drug use, intolerance of physical discomfort, smoking medication adherence, and 3- and 6-month smoking and substance use outcomes (by VAR versus NRT). RESULTS: Smokers with OUD did not differ on pretreatment alcohol or smoking measures while reporting significantly more drug use days. Smokers with OUD versus NOUD had significantly fewer days adherent to VAR or placebo capsules but not to patches, and were more tolerant of physical discomfort. While smoking and heavy drinking days at follow-ups did not differ by diagnosis, smokers with OUD had significantly more drug use days in months 4-6 when assigned to VAR (16.4 days) than to NRT (8.1 days). CONCLUSIONS:NRT might be a better choice than VAR for smokers with OUD due to lower adherence and more drug use days with VAR. However, this novel comparison of smoking pharmacotherapy response in smokers with OUD versus NOUD needs to be confirmed with larger numbers of participants. Published by Elsevier Inc.
Entities:
Keywords:
Opioid use disorder; Smoking treatment; Substance use disorder; Tolerance for discomfort; Transdermal nicotine; Varenicline
Authors: Barbara A Flannery; John P Allen; Helen M Pettinati; Damaris J Rohsenow; Ron A Cisler; Raye Z Litten Journal: Alcohol Clin Exp Res Date: 2002-03 Impact factor: 3.455
Authors: David Gonzales; Stephen I Rennard; Mitchell Nides; Cheryl Oncken; Salomon Azoulay; Clare B Billing; Eric J Watsky; Jason Gong; Kathryn E Williams; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Kimber P Richter; Ashley K Hamilton; Sandra Hall; Delwyn Catley; Lisa S Cox; James Grobe Journal: Exp Clin Psychopharmacol Date: 2007-04 Impact factor: 3.157
Authors: Joanna M Streck; Stacey C Sigmon; Jeffrey Priest; Cecilia L Bergeria; Danielle R Davis; John R Hughes; Andrea C Villanti; Jennifer W Tidey; Sarah H Heil; Diann E Gaalema; Maxine L Stitzer; Stephen T Higgins Journal: Exp Clin Psychopharmacol Date: 2020-02-06 Impact factor: 3.157
Authors: Mohammad Rifat Haider; Monique J Brown; Rajat Das Gupta; Sabrina Karim; Bankole Olatosi; Xiaoming Li Journal: Subst Use Misuse Date: 2020-07-07 Impact factor: 2.164